^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

anti-CD19-CAR

i
Other names: anti-CD19-CAR, anti-CD19 chimeric antigen receptor T cell therapy, CD19 Chimeric Antigen Receptor (CAR) redirected autologous T-cells
Associations
Company:
Kecellitics Biotech
Drug class:
CD19-targeted CAR-T immunotherapy
Related drugs:
Associations
almost2years
Immunotherapy With CD19 CAR T-cells for B-Cell Leukemia (clinicaltrials.gov)
P1, N=100, Not yet recruiting, Kecellitics Biotech Company Ltd | Trial completion date: Aug 2022 --> Aug 2024 | Trial primary completion date: Aug 2021 --> Aug 2023
Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
|
CD19 expression
|
anti-CD19-CAR